Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
    • Charitable Giving
    • Philanthropic Consulting
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Crypto
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial

BY Benzinga
— 9:08 AM ET 06/24/2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus

Europe Backs Novavax's COVID-19 Shot For Adolescents

The European Union has recommended expanded conditional approval of Novavax Inc's NASDAQ:NVAX Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for adolescents ages 12-17. 

Separately, the Taiwan Food and Drug Administration has granted emergency use authorization for the Nuvaxovid COVID-19 vaccine in individuals ages 18 and over.

Novavax and Taiwan have executed a supply agreement, and the doses for Taiwan would represent the first shipment of Nuvaxovid to a country participating under the COVAX Facility.

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Omicron Efficacy 

Sanofi SA SNY and GSK plc GSK have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. 

"Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement.

In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID and 72% against infections specifically caused by the omicron variant.

BioNTech's Testicular Cancer CAR-T Receives Priority Medicines Tag In Europe

The European Medicines Agency has granted Priority Medicines designation to BioNTech SE's NASDAQ:BNTX BNT211 for the third- or later-line treatment of testicular germ cell tumors.

The product candidate is currently being investigated in an ongoing Phase 1/2 study to evaluate the safety and preliminary efficacy in heavily pretreated patients with relapsed or refractory advanced solid tumors.

FDA Slaps Clinical Hold On Sarepta's Duchenne Trial

The FDA has instituted a clinical hold on Sarepta Therapeutics Inc's NASDAQ:SRPT SRP-5051 (vesleteplirsen) trial in Duchenne muscular dystrophy patients who are amenable to exon 51 skipping. 

The hold in Part B of Study 5051-201, also known as MOMENTUM, follows a serious adverse event of hypomagnesemia (low serum magnesium level in the blood). 

FDA is requesting information on all cases of hypomagnesemia, including a small number of non-serious grade 2 cases.

Celyad Announces Management Transition

Celyad Oncology SA's NASDAQ:CYAD CEO & CFO Filippo Petti has resigned to pursue other opportunities.

Michel Lussier, a co-founder of the company, has been named the interim CEO.

FDA Sets AdComm Meeting For Cytokinetics's Omecamtiv Mecarbil Application

The FDA has scheduled the Cardiovascular and Renal Drugs Advisory Committee meeting for Cytokinetics Incorporated NASDAQ:CYTK's marketing application for omecamtiv mecarbil.

The meeting is scheduled for Dec. 13, 2022. The FDA has assigned a PDUFA target date of February 28, 2023. 

Omecamtiv mecarbil is a cardiac myosin activator for heart failure with reduced ejection fraction.

Insider Trading

Tracon Pharmaceuticals Inc NASDAQ:TCON: Opaleye Management reported purchasing 841,989 shares at an average price of $1.31/share in form 4 filing.

Voyager Therapeutics Inc NASDAQ:VYGR: EcoR1 Capital LLC reported purchasing 477,400 shares at an average of $5.58/share in form 4 filing.

On The Radar

PDUFA Dates

Bristol Myers Squibb & Co NYSE:BMY: Supplemental marketing application for Breyanzi for relapsed or refractory LBCL after the failure of first-line therapy is currently under FDA Priority Review.

More BNTX News

  • BioNTech Gets EMA's Priority Medicines Status For Testicular Cancer Drug
    Benzinga - 2:42 PM ET 06/23/2022
  • BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer
    GlobeNewswire - 11:00 AM ET 06/23/2022
  • BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa
    GlobeNewswire - 6:00 AM ET 06/23/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close